Shionogi & Co. on Friday submitted an application for conditional early approval for Japan's first domestically developed COVID-19 pill, which the government hopes could be a “trump card” in preventing serious illness and bringing an end to the prolonged pandemic.
Prime Minister Fumio Kishida has signaled the central government will expedite the review process to pave the way for a swift approval if the drug's efficacy and safety are confirmed. Shionogi has said it hopes to begin shipments of the treatment as soon as the end of this month.
If formally approved, Shionogi’s experimental drug would become the third COVID-19 oral anti-viral pill for the treatment of mild symptoms to be given the OK in Japan, after Merck & Co.'s molnupiravir and Pfizer Inc.’s Paxlovid.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.